NIH Awards Biodel Grant to Develop Ultra-Rapid-Acting Insulin for Use in Artificial Pancreas

Shares
The Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has awarded Biodel a grant for the development of concentrated ultra-rapid-acting insulin formulations for use in an artificial pancreas, also known as a closed loop pump system.

The two-year, $582,473 grant, is intended to fund research to develop Biodel’s proprietary ultra-rapid-acting insulin product candidate at high concentrations suited to provide sufficient quantities of insulin in an external artificial pancreas pump device that has a limited volume capacity.

Currently, regular insulin at concentrations of 500 units per milliliter is used to treat extremely insulin resistant patients with diabetes. While these formulations are 5-times more concentrated than typical insulin presentations, they have a prolonged duration of action that may be undesirable for use with an artificial pancreas.

Concentrated formulations of Biodel’s ultra-rapid-acting insulin may be absorbed more rapidly than existing concentrated insulin formulations and may therefore become an important component of an effective step in the development of an artificial pancreas.

 
0 0 vote
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
Copyright © 2009-2020 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
DMCA Compliant
0
Would love your thoughts, please comment.x
()
x